Adlyxin (lixisenatide) / Zealand Pharma, Sanofi, Royalty - LARVOL DELTA

GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK (DDW 2025) - "We constructed 1-1 propensity-score (PS)-matched cohorts of patients initiating GLP-1RAs (semaglutide, liraglutide, exenatide, dulaglutide, albiglutide, tirzepatide, or lixisenatide) or DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin or sitagliptin). In patients with compensated MASH cirrhosis, GLP-1RAs were associated with significantly lower rates of hepatic decompensation and all-cause mortality compared to DPP-4 inhibitors. These findings suggest a potential therapeutic benefit of GLP-1RAs in this population, warranting further validation through prospective studies."

Clinical • CNS Disorders • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Oncology • Renal Disease • Solid Tumor

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. (PubMed, Pharmacol Res) - "To date, clinical trials have shown that three GRA, exenatide, liraglutide and lixisenatide can improve motor deficits as an add-on therapy in PD patients and liraglutide can improve cognitive function in AD patients. The dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists have been demonstrated to have beneficial effects in AD and PD mice models. Overall, GRA are highly promising novel drugs, but future clinical studies should identify which subsets of patients should be targeted as potential candidates for their symptomatic and/or neuroprotective benefits, investigate whether combinations with other classes of drugs can further augment their efficacy, and evaluate their long-term disease-modifying and adverse effects."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Diabetes • Genetic Disorders • Huntington's Disease • Inflammation • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease • Type 2 Diabetes Mellitus

ADVERSE EVENTS OF PANCREATITIS ASSOCIATION TO VARIOUS GLP-1 RECEPTOR AGONIST: ANALYSIS PER US FDA ADVERSE REPORTING SYSTEM (DDW 2025) - "Lixisenatide has highest PRR 4.74 (CI 2.22-10.11, P <0.001). Among GLP-1 RA, there are differences in pancreatitis related AE PRR in FAERS. Higher association is found between with liraglutide and exenatide for pancreatitis, chronic pancreatitis and acute pancreatitis which is in line with earlier reports from clinical trial meta-analysis and real word AE assessments. Newer GLP-1 RA tirzepatide and dulaglutide, as per our assessment, are reported lower PRR and thus lower association signal with pancreatitis related AEs."

Adverse events • Gastrointestinal Disorder • Pancreatitis

ANALYSIS OF UPPER GASTROINTESTINAL ADVERSE EVENTS AMONG GLP-1 RECEPTOR AGONISTS REPORTED IN US FDA ADVERSE EVENT REPORTING SYSTEM: FOCUS ON GERD, PEPTIC ULCER AND HEMATEMESIS (DDW 2025) - "Results PRR for GERD AEs are higher in case of lixisenatide PRR 2.34 (CI 0.87-6.32, P =0.0926), semaglutide PRR 1.45 (CI 1.31-1.60, P <0.001) and liraglutide PRR 1.30 (CI 1.18-1.43, P <0.001)...PRR for peptic ulcer AEs are higher in case of semaglutide PRR 1.58 (CI 1.03-2.43, P =0.0352), liraglutide PRR 1.48 (CI 0.99-2.23, P =0.0580) and Exenatide PRR 1.46 (CI 1.07-1.99, P =0.0165)...Though in general similar AEs are seen within this class of drugs, this study indicates there might be different AE risks with different GLP-1 RA. Dulaglutide and Tirzepatide seem to have lower reports GERD and peptic ulcer related AEs."

Adverse events • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer

The LIXIPARK trial: lixisenatide to treat patients with early Parkinson disease (PD) (JSNE 2025) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists. (PubMed, Curr Drug Saf) - "Qualified healthcare practitioners must educate the patients administering the GLP- 1 RAs to minimize preventable DRPs. Also, careful and frequent monitoring of GLP-1 RAs improves therapeutic outcomes by ruling out DRPs. Healthcare practitioners should comply with approved therapeutic guidelines to enhance the quality of GLP-1 RAs treatment."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials (ESPE-ESE 2025) - "Until recently, the approved treatments for pediatric patients encompassed only metformin and insulin... We systematically searched PubMed, Embase, and Cochrane databases in December 2023 for randomized controlled trials (RCTs) that compared GLP-1 RA (exenatide, lixisenatide, dulaglutide, liraglutide or semaglutide) with placebo in patients from ages 8 to 19 years old, for the treatment of T2DM... In this meta-analysis, the use of GLP-1 RA in pediatric patients with T2DM yields significant reductions in HbA1c levels compared to placebo, indicating its potential as an effective adjunctive therapy. However, it’s noteworthy that there were non-significantly changes in fasting glucose concentration and reduction in BMI compared to placebo."

Late-breaking abstract • Retrospective data • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Pediatrics • Type 2 Diabetes Mellitus

Association of Glucagon-Like Peptide-1 Agonists and Mortality Among Patients With Idiopathic Pulmonary Fibrosis (ATS 2025) - "We included patients older than 18 years with a diagnosis of IPF (ICD-10 J84.112) and stratified the data according to GLP-1 agonist use, including liraglutide, lixisenatide, tirzepatide, dulaglutide, exenatide, and semaglutide...Notably, less than 7.5% of these patients were on antifibrotics, including pirfenidone or nintedanib...However, the infrequent use of antifibrotics in this analysis raises questions about their underutilization. Further prospective research is needed to better understand GLP-1 agosnists role in patients with IPF."

Clinical • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Metabolic Disorders • Nephrology • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

DUAL GLP-1/GIP RECEPTOR AGONISTS THAT CAN CROSS THE BBB SHOW SUPERIOR NEUROPROTECTIVE EFFECTS (ADPD 2025) - "Methods Bydureon (exenatide) and Adlyxin (lixisenatide) showed disease-modifying protective effects in patients with PD in two phase 2 clinical trials...NLY01, a pegylated form of exenatide that can't cross the BBB did not show any effects in PD patients in a phase 2 trial...Results Currently, two phase 3 trials are ongoing, testing the diabetes drug Ozempic/Wegovy (semaglutide) in AD patients...In animal models of AD or PD, dual agonists were able to protect neurons better than GLP-1 class drugs such as liraglutide, semaglutide or tirzepatide that were designed to treat diabetes and that stay in the blood for longer periods. Conclusions The dual GLP-1/GIP receptor agonist KP405 (DA5-CH) is currently in a phase 1 clinical trial and Results will be shared at the conference."

Alzheimer's Disease • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study. (PubMed, Health Sci Rep) - "Semaglutide (45.7%, 95% CI: 41.8%-49.5%) was the most commonly used GLP-1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%-40.8%). Other GLP-1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%-20.1%), Exenatide (14.1%, 95% CI: 11.5%-17.0%), Albiglutide (7.0%, 95% CI: 5.1%-9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%-10.9%...This study provides the first prevalence estimate of GLP-1RA use among HCPs and GLP1-Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self-prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks."

Journal • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study. (PubMed, J Diabetes Res) - "A protective role of FRCs in diabetic ASCVD has been proven, but their protective role in CKD was not observed. The significant improvements in glycemic and weight control, as well as in TODs, suggest that therapy simplification may represent a more favorable approach compared to the continuation of previous ICT even in patients characterized by high baseline TDD and HbA1c levels."

Journal • Retrospective data • Chronic Kidney Disease • Diabetes • Hypoglycemia • Metabolic Disorders • Nephrology • Pain • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis. (PubMed, Diabetes Ther) - "Tirzepatide demonstrated statistically significantly greater reductions in HbA1c and body weight when compared with selected GLP-1 RAs and placebo in patients with T2DM treated with basal insulin. Overall, the safety profile of tirzepatide was similar to that of GLP-1RAs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. (PubMed, J Drugs Dermatol) - "Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia. 2025;24(4):413-415. doi:10.36849/JDD.8605."

Clinical • Retrospective data • Alopecia • Atopic Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Type 2 Diabetes Mellitus

Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders. (PubMed, Neurosci Biobehav Rev) - "We observed that GLP-1 and GLP-1 RAs modulate molecular and cellular changes known to govern the phenomenology of neurodegenerative diseases. Future research should examine the interaction between signaling molecules, neuronal subpopulations, and cognitive effects affected by GLP-1 and GLP-1 RA administration."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. (PubMed, Int J Impot Res) - "Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide). Despite statistically significant chi-squared values (P < 0.0001), low ROR (0.41, 95% Confidence interval (CI): 0.36-0.48), PRR (0.41, 95% CI: 0.36-0.48), and RRR (0.42, 95% CI: 0.36-0.48) suggest a weak association. These findings underscore the need for monitoring as GLP-1 use expands, though overall patient risk remains low."

Journal • Diabetes • Erectile Dysfunction • Metabolic Disorders • Sexual Disorders • Type 2 Diabetes Mellitus

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. (PubMed, Diabetes Obes Metab) - "The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations."

Clinical • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence (EASL 2025) - "Primary outcomes were the development of decompensated cirrhosis and all-cause mortality in patients treated with GLP-1 analogs (semaglutide, tirzepatide, dulaglutide, exenatide, lixisenatide) compared to patients treated with bariatric surgery (gastric bypass, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, vertical band gastroplasty)... Out of 545,931 patients with MASLD, 73,339 (13.44%, median 733 days) patients were treated with GLP1 analog, 38,541 (7.06%, median 690 days) sodium-glucose cotransporter 2 (SGLT 2) inhibitors and 29,917 (5.48%, median 832 days) received other weight loss medications (naltrexone, topiramate or phentermine)... GLP-1 analogs are increasingly being used in patients with MASLD. GLP-1 analogs and bariatric surgery reduce the risk of decompensated cirrhosis in obese patients with MASLD. Our results indicate that patients with MASLD treated with GLP-1 analogs have a lower risk of decompensated cirrhosis and better overall..."

Bariatric surgery • Clinical • HEOR • Real-world • Real-world evidence • Surgery • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Oncology • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Solid Tumor

THE LIXIPARK TRIAL, A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF LIXISENATIDE IN PATIENTS WITH EARLY PARKINSON'S DISEASE (PD) (ADPD 2025) - "Secondary endpoints included: (a) mean changes from baseline in MDS-UPDRS I and II in ON (month-12), and levodopa equivalent daily dosage (LEDD) (month-12); (b) mean MDS-UPDRS III score in the practically defined OFF condition at month-14 (end of wash-out) and (c) safety and tolerability. Conclusions Lixisenatide had beneficial effects on motor progression in patients with early PD, supporting a disease-modifying effect warranting further investigations and comparisons with other GLP1 agonists currently under assessment for neuroprotection PD."

Clinical • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease. (PubMed, Neural Regen Res) - "In addition, lixisenatide inhibited α-synuclein phosphorylation and seeding between neurons, mediated by neuronal lymphocyte-activation gene 3 expression. This study provides new insights into the mechanism underlying the disease-modifying effects of glucagon-like peptide-1 receptor agonists in the treatment of Parkinson's disease."

Journal • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus • LAG3

PREOPERATIVE GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST ASSOCIATED WITH IMPROVED POSTOPERATIVE OUTCOMES (IARS-SOCCA 2025) - "We first compared patients who were treated with a GLP1-RA (lixisenatide, albiglutide, tirzepatide, dulaglutide, liraglutide, semaglutide, or exenatide) within 6 months of a procedure with those who were not treated. This large analysis assessed the effects of holding GLP1-RAs before surgery on postoperative outcomes. GLP1-RAs may protect against postoperative aspiration and other adverse outcomes; holding GLP1-RA may be harmful."

Alzheimer's Disease • Anesthesia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Dementia • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Multiple Sclerosis • Myocardial Infarction • Nephrology • Obesity • Oncology • Pain • Pancreatitis • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "However, safety is still of concern. Further high-quality studies with standardized protocols and larger sample sizes are needed to confirm our findings."

Journal • Retrospective data • Review • CNS Disorders • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus

Preoperative Weight Loss Before Total Joint Arthroplasty Using Novel GLP-1 Agonists (AAOS 2025) - "GLP-1s were categorized as Food and Drug Administration (FDA)-approved for weight loss (Group 1: semaglutide and liraglutide) versus FDA-approved for diabetes or under investigation for weight loss (Group 2: dulaglutide, exenatide, lixisenatide, efpeglenatide, tirzepatide plus Group 1 medications). The prevalence of preoperative GLP-1s before TJA tripled to 4.6% from 2019 to 2022, and preoperative weight change on GLP-1s varied considerably. GLP-1s were not associated with increased postoperative risks but investigational GLP-1s before TJA require further study."

Anesthesia • Diabetes • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics

Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis. (PubMed, Clin Spine Surg) - "Our findings demonstrate a statistically significant lower incidence of pseudarthrosis among patients treated with GLP-1 agonist therapy at all timepoints within this study-from 6-months to 2-years postoperatively, suggesting a potentially beneficial effect of GLP-1 agonist therapy in promoting fusion success in multilevel cervical spine surgery. Fundamentally, this aligns with the pharmacodynamic nature of GLP-1 agonists: as compounds that enhance osteoblastic activity and suppress osteoclastic activity, thereby facilitating bone formation and attenuating bone resorption. Further investigation into the mechanistic underpinnings of GLP-1 agonists' effects on bone metabolism may pave the way for enhancing the success of cervical spine surgery."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Nicotine Addiction • Obesity • Orthopedics • Osteoarthritis

Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (PubMed, Nervenarzt) - "Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist...Typical accompanying adverse reactions are gastrointestinal side effects, such as nausea, vomiting, diarrhea, eructation and gastroesophageal reflux. More severe side effects include pancreatitis, allergic reactions, renal function disorders and possibly an increased risk of thyroid cancer."

Journal • Review • Addiction (Opioid and Alcohol) • Allergy • Alzheimer's Disease • Binge Eating Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Endocrine Cancer • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Oncology • Pancreatitis • Psychiatry • Solid Tumor • Thyroid Gland Carcinoma